TITLE

Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study

AUTHOR(S)
Chia-Lin Tseng; Oxlade, Olivia; Menzies, Dick; Aspler, Anne; Schwartzman, Kevin
PUB. DATE
January 2011
SOURCE
BMC Public Health;2011, Vol. 11 Issue 1, p55
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The development of a successful new tuberculosis (TB) vaccine would circumvent many limitations of current diagnostic and treatment practices. However, vaccine development is complex and costly. We aimed to assess the potential cost effectiveness of novel vaccines for TB control in a sub-Saharan African country - Zambia - relative to the existing strategy of directly observed treatment, short course (DOTS) and current level of bacille Calmette-Guérin (BCG) vaccination coverage. Methods: We conducted a decision analysis model-based simulation from the societal perspective, with a 3% discount rate and all costs expressed in 2007 US dollars. Health outcomes and costs were projected over a 30-year period, for persons born in Zambia (population 11,478,000 in 2005) in year 1. Initial development costs for single vaccination and prime-boost strategies were prorated to the Zambian share (0.398%) of global BCG vaccine coverage for newborns. Main outcome measures were TB-related morbidity, mortality, and costs over a range of potential scenarios for vaccine efficacy. Results: Relative to the status quo strategy, a BCG replacement vaccine administered at birth, with 70% efficacy in preventing rapid progression to TB disease after initial infection, is estimated to avert 932 TB cases and 422 TBrelated deaths (prevention of 199 cases/100,000 vaccinated, and 90 deaths/100,000 vaccinated). This would result in estimated net savings of $3.6 million over 30 years for 468,073 Zambians born in year 1 of the simulation. The addition of a booster at age 10 results in estimated savings of $5.6 million compared to the status quo, averting 1,863 TB cases and 1,011 TB-related deaths (prevention of 398 cases/100,000 vaccinated, and of 216 deaths/100,000 vaccinated). With vaccination at birth alone, net savings would be realized within 1 year, whereas the prime-boost strategy would require an additional 5 years to realize savings, reflecting a greater initial development cost. Conclusions: Investment in an improved TB vaccine is predicted to result in considerable cost savings, as well as a reduction in TB morbidity and TB-related mortality, when added to existing control strategies. For a vaccine with waning efficacy, a prime-boost strategy is more cost-effective in the long term.
ACCESSION #
59162748

 

Related Articles

  • Potential Cost-Effectiveness of a New Infant Tuberculosis Vaccine in South Africa - Implications for Clinical Trials: A Decision Analysis. Ditkowsky, Jared B.; Schwartzman, Kevin // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Novel tuberculosis vaccines are in varying stages of pre-clinical and clinical development. This study seeks to estimate the potential cost-effectiveness of a BCG booster vaccine, while accounting for costs of large-scale clinical trials, using the MVA85A vaccine as a case study for estimating...

  • `Poor' vaccine ruled out in TB puzzle. Day, Michael // New Scientist;7/13/96, Vol. 151 Issue 2038, p14 

    Reports on a British study designed to explain why the BCG vaccine often fails to protect against tuberculosis (TB) in developing countries. Rejection of notion that poor quality of vaccines render the TB treatment ineffective; Exposure of children in tropical countries to numerous other...

  • Improving vaccines against tuberculosis. Britton, Warwick J; Palendira, Umaimainthan // Immunology & Cell Biology;Feb2003, Vol. 81 Issue 1, p34 

    Summary Tuberculosis remains a major cause of mortality and physical and economic deprivation worldwide. There have been significant recent advances in our understanding of the Mycobacterium tuberculosis genome, mycobacterial genetics and the host determinants of protective immunity....

  • BCG campaign may be delayed.  // Pulse;8/19/2002, Vol. 62 Issue 32, p8 

    Reports on the possible delay of the start of the BCG school vaccination campaign in Great Britain due in October 2002, following the withdrawal of the only tuberculosis vaccine approved in the country.

  • New TB vaccination programme.  // Practice Nurse;7/29/2005, Vol. 30 Issue 2, p7 

    This article reports that the British government will replace the universal BCG vaccination program with a program of targeted vaccination for individuals that have the greatest risk.

  • Addressing your patients' concerns on BCG vaccine. Baxter, David // Pulse;10/21/2002, Vol. 62 Issue 40, p59 

    Reports on the withdrawal of Bacille Calmette Guerin (BCG) tuberculosis (TB) vaccine in Great Britain. Background on the BCG vaccine; Reasons for the withdrawal of the TB vaccine from the market; Role of TB vaccines in the control of tuberculosis in England and Wales; Tips for general practice...

  • BCG vaccine works well in preventing TB. Rodman, Morton J.; Hurley, Mary Lou // RN;May94, Vol. 57 Issue 5, p82 

    Reports on a study on the efficacy of Bacillus Calmette-Guerin (BCG) vaccine in preventing tuberculosis infection. Consideration of broader use of the vaccine in the country; Analysis of prospective trials and case-control studies.

  • TB vaccines move a step closer. Berger, Abi // New Scientist;5/27/95, Vol. 146 Issue 1979, p19 

    Reports on University of Surrey researchers' perfection of a gene replacement technique which could speed up the search for new tuberculosis vaccines to replace BCG. Removal of the part of a bacterium that spreads the infection as core process of vaccine development; Identification of virulent...

  • MVA-85A vaccine well tolerated in BCG-vaccinated infants.  // Reactions Weekly;2/23/2013, Issue 1440, p3 

    The article reports that as per a phase 2b safety and efficacy trial a good safety profile and no efficacy against tuberculosis was evident in healthy infants previously vaccinated with Bacille Calmette-Guérin (BCG) who received modified vaccinia Ankara (MVA-85A) tuberculosis vaccine.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics